Other targeted treatments addressing small defined sub-sets of colorectal cancers include NTRK inhibitors for colorectal cancers with NTRK fusions and specific KRAS G12C inhibitors for cancers with this KRAS substitution [8,9]. The gene discussed is KRAS; the disease is cancer.